Patient Characteristics | N (%) | Scans | N (%) | ||
Clinical Indications | Staging | 17 (39%) | Positive Scans | 41 (93%) | |
Biochemical Recurrence | 15 (34%) | Negative Scans | 3 (7%) | ||
Restaging after therapy | 12 (27%) | Lesions* | |||
Age (years) Range: 48 - 84 years, Mean: 69.18 ± 7.35 years | ≤50 | 1 (2%) | Prostatic Fossa Involvement (T stage) 34 (83%) | T2u | 13 (38%) |
51 - 60 | 3 (7%) | ||||
61 - 70 | 26 (59%) | T2m | 03 (9%) | ||
71 - 80 | 11 (25%) | T3b | 09 (26%) | ||
≥81 | 3 (7%) | T4 | 07 (21%) | ||
Serum PSA Level (ng/ml) Range: <0.025 - 544 ng/ml, Median 12.3 ± 103 ng/ml | ≤10 | 23 (52%) | Regional Nodal Involvement (N stage) 17 (41%) | N1 | 05 (29%) |
11 - 20 | 7 (16%) | ||||
21 - 100 | 9 (20%) | N2 | 11 (65%) | ||
≥101 | 5 (11%) | Distant Metastasis (M stage) 23 (56%) | M1a | 11 (48%) | |
Gleason Score | <7 | 1 (2%) | |||
7 | 22 (50%) | M1b | 17 (74%) | ||
8 | 15 (34%) | M1c | 05 (22%) | ||
≥9 | 6 (14%) |